端午节期间，PD(L)1*VEGF双抗及GLP1领域重磅事件频出： 1）康方生物&summit公布伊沃西单抗针对2L EGFRm的全球临床HARMONI的顶线数据，我们认为核心结论如下： a）PD(L)1*VEGF双抗在EGFRm突变后线具有一定有效性，且中位随访时间较短，需要更长时间随访评估； 【国泰海通医药】热门领域重磅交易再起，继续推荐创新药板块 端午节期间，PD(L)1*VEGF双抗及GLP1领域重磅事件频出： 1）康方生物&summit公布伊沃西单抗针对2L EGFRm的全球临床HARMONI的顶线数据，我们认为核心结论如下： a）PD(L)1*VEGF双抗在EGFRm突变后线具有一定有效性，且中位随访时间较短，需要更长时间随访评估； b）HARMONI研究验证了中美临床的一致性；c）FDA指出 【国泰海通医药】热门领域重磅交易再起，继续推荐创新药板块 连续的PD(L)1*VEGF资产对外授权反应了MNC对于相关类型药物的看好，凭借MNC的临床和资金壁垒，我们认为 其有望找到更多优势的细分人群做出临床获益。 我们也看好ROG、ABBV等其他MNC的需求，国内荣昌生物、宜明昂科、华海药业、华兰生物、神 ...

市场是不是应该期待6月下旬的ADA（美国糖尿病学会年会）上，有新的大额BD交易爆发？ 2025年6月2日，翰森制药与美国再生元（Regeneron）共同宣布一项重磅许可合作：再生元以8000万美 元首付款、最高19.3亿美元里程碑付款获得翰森在研GLP-1/GIP双受体激动剂HS-20094在大中华区以外 的全球独家开发与商业化权利。 HS-20094是一款每周皮下注射的候选药物，在超过千例受试者的II期试验中展现出与礼来tirzepatide（全 球唯一获批GLP-1/GIP双激动剂）相近的显著减重和安全数据，目前正于中国开展肥胖症III期和糖尿病 2b期试验。 值得注意的是，这笔交易虽然还是GLP-1/GIP，但对于购买方再生元来说，目的已经非常明确，联用自 己的肌肉保持产品，进入减脂增肌的减肥药2.0时代。 再生元联手翰森：减肥药2.0时代的起点？ 在2025年Q1财报电话会上，再生元管理层明确传递出对肥胖治疗业务的新态度：公司将"致力于通过提 高减肥质量来推进更好的肥胖治疗"，关注点不仅是减轻体重数字，更强调"高质量、持续的减重"。 再生元联合创始人兼首席科学官George Yancopoulos博士 ...

Core Viewpoint - The prevention of childhood obesity is crucial and should begin during pregnancy and continue through early childhood, emphasizing the importance of balanced nutrition and physical activity [1][2][3][4] Group 1: Causes of Childhood Obesity - Childhood obesity is caused by multiple factors, primarily lifestyle choices such as excessive eating and insufficient physical activity, leading to an energy imbalance [1] - Obesity can lead to serious health complications, including cardiovascular diseases, type 2 diabetes, and psychological issues, which may persist into adulthood [1] Group 2: Prevention Strategies - Prevention should start during pregnancy, with mothers maintaining a balanced diet and appropriate physical activity to avoid excessive fetal growth [2] - Exclusive breastfeeding for the first six months is essential, followed by gradual introduction of solid foods while continuing breastfeeding until the age of two [2] Group 3: Healthy Eating Habits - Parents should ensure children have a balanced diet with a variety of foods, including grains, proteins, vegetables, and fruits, while controlling oil and salt intake [3] - Daily milk intake should be encouraged at approximately 300-500 milliliters, and water intake should be around 800-1400 milliliters, while limiting sugary drinks to prevent excess calorie consumption [3] Group 4: Physical Activity Recommendations - Infants should engage in at least 30 minutes of tummy time, while toddlers should have a minimum of 180 minutes of physical activity daily [4] - School-aged children should accumulate at least 60 minutes of moderate to vigorous physical activity each day, including strength training exercises [4] - It is important to limit sedentary behavior, encouraging breaks from screen time to promote movement [4] Group 5: Management of Existing Obesity - For already obese children, lifestyle adjustments should be prioritized, with medical intervention considered only if lifestyle changes are ineffective or if complications arise [4]

今年4月，国家卫生健康委办公厅、国家中医药局综合司联合发布《关于做好健康体重管理门诊设置与 管理工作的通知》，要求国家卫生健康委、国家中医药局属(管)、省(区、市)属综合医院、儿童医院、 中医医院要在2025年6月底前基本实现健康体重管理门诊设置全覆盖。 目前体重管理门诊开设情况如何？公立医院在健康减重方面有什么"秘诀"？"新华视点"记者在多地进行 了调查。 走进北京大学第一医院多学科联合减重门诊，候诊区坐满了人。42岁的王女士身高1.65米，体重达85公 斤，体检时血糖偏高让她心急如焚。"以前减肥盲目节食，总是反弹。"王女士说，"听说这里能科学减 重，就赶紧来了。" 像王女士这样的案例并非个例。国家卫生健康委数据显示，我国18岁及以上居民超重及肥胖率已超 50%。肥胖及相关代谢性疾病，如高血压、糖尿病、高血脂等，已成为影响国民健康的重要公共卫生问 题。 肥胖率攀升的背后，是现代社会生活方式的深刻变化。快节奏的工作模式让"久坐"成为常态，外卖、快 餐等高热量饮食占据日常餐桌，运动时间却严重不足。 此外，儿童肥胖问题同样不容忽视。中国疾控中心数据显示，当前，我国6岁至17岁儿童青少年超重肥 胖率约为19%。专家 ...

整理 | GLP1减重宝典内容团队 无论是借助有效的新药减肥，还是通过减肥手术减肥，或是减少卡路里摄入并增加运动，总有一天体重秤上的数字会停止下降，这时会进入无 奈的减重平台期。 研究表明， 胃绕道手术和 Wegovy、Zepbound 等新型减肥药之所以如此有效，部分原因是它们使进入平台期的时间增加了一倍。没有药物和 手术干预，进入平台期平均时间为一年，药物和手术干预使进入平台期延缓了一年。与单纯减少卡路里摄入相比，人们能够更长时间地减肥。 ▍ 为什么出现减重平台期 身体通过试图保持摄入的卡路里和燃烧的卡路里之间的平衡来调节体重。当我们消耗或减少卡路里，并开始燃烧储存的能量时，食欲就会开始 告诉我们要吃更多。 研究表明，一个人减掉的体重越多，食欲就会越强 ，直到抵消甚至完全抵消他们最初为减肥所做的所有努力。 体重平台期的出现，主要源于基础代谢率的下降。 当体重减少大约5公斤时，人体的基础代谢率会自动下调。一旦基础代谢率下降，身体就会 重新进入能量储存模式，不再响应减重需求，从而导致体重停滞不降。 体重调定点理论指出，人体体重存在一个"自然调定点" ，身体会通过调节代谢率和饥饿感来维持体重在这个平衡点附近10 ...

这项临床研究标志着中国自主研发的创新减重药物临床研究迈入国际领先行列，有望改写国内外超重和肥胖疾病的临床治疗和指南。 当地时间5月25日，《新英格兰医学杂志》（NEJM）公布了一项来自中国研究者的GLP-1类减重创新药玛仕度肽的临床研究成果。这也是中国GLP-1类减重 药乃至整个代谢和内分泌疾病领域的创新药临床研究成果首次登上国际医学权威期刊。 最新公布的研究来自于北京大学人民医院纪立农教授领衔开展的3期、双盲、安慰剂对照试验（GLORY-1）结果。GLORY-1是首个在中国超重或肥胖受试者 中评估玛仕度肽疗效和安全性的三期临床试验，标志着中国自主研发的创新减重药物临床研究迈入国际领先行列，有望改写国内外超重和肥胖疾病的临床治 疗和指南。 他还称，玛仕度肽GLORY-1研究登顶全球最权威的临床医学期刊《新英格兰医学杂志》，不仅代表了中国在内分泌代谢领域的创新研究成果得到了国际认 可，也再次证实中国创新药物的研发能力与生物科技创新水平已走在了全球前列。 具体而言，研究结果显示，在用药48周时，4mg玛仕度肽组和6mg玛仕度肽组体重减轻15%至少的受试者比例分别达到35.7%和49.5%以上。根据本月早些时 候礼 ...

Group 1 - The pharmaceutical and biotechnology industry is experiencing a positive export trend, with a 4.39% year-on-year increase in pharmaceutical exports in Q1 2025, and a 9.6% increase in exports to the U.S. after a reduction in short-term tariff impacts [1] - In the innovative drug sector, China's research and development efficiency is improving, with 31% of multinational pharmaceutical companies introducing molecules from China in 2024, and an increase in early project collaborations [1] - The weight loss sector is seeing intensified global competition, with companies like Novo Nordisk and Eli Lilly accelerating their development of oral GLP-1 drugs, while Chinese firms are making breakthroughs in small molecules and peptide carriers [1] Group 2 - In the medical device sector, general CAR-T technologies such as CT0596 and TyU19 are demonstrating efficacy and economic advantages in treating tumors and autoimmune diseases, potentially becoming mainstream in the future [1] - The industry's innovative payment systems are gradually improving, and there is a peak in overseas licensing activities [1] - The Guotai pharmaceutical ETF (159377) tracks the ChiNext pharmaceutical and health index (399275.SZ) and is characterized by high volatility, with daily price fluctuations reaching up to 20%, making it noteworthy for investors [1]

Group 1 - The NHNE China International Health Nutrition Expo 2025 will take place from May 21 to 23, showcasing over 40,000 square meters of exhibition space with participation from 1,200 leading global brands and thousands of health nutrition products [1][3] - The expo serves as a platform for health nutrition companies to adjust strategies and expand into the domestic market, facilitating deep exchanges and cooperation with over 100,000 domestic distributors, retailers, and e-commerce platforms [3][5] - The event marks the 10th anniversary of NHNE, reflecting on its commitment to making nutrition accessible and its service to over 5,000 quality brands [5] Group 2 - The number of health nutrition companies focusing on weight management has significantly increased, with around 300 companies participating in the expo, offering over 1,000 SKUs across various sectors [7] - The expo will feature a focus on global health nutrition industry trends, including the launch of over 50 innovative products and industry white papers, driving the industry towards clinical evidence and international standards [9] - NHNE emphasizes the importance of technology in driving industry innovation, hosting a series of scientific conferences to discuss cutting-edge research and technology applications [11] Group 3 - Digital marketing strategies, including live broadcasts and private domain influencers, are becoming essential for companies to enhance brand awareness and attract consumer attention [13] - The expo aims to meet consumer demand for health nutrition products and promote industry upgrades under national strategic guidance, while also fostering innovation through technological advancements [15]

整理 | GLP1减重宝典内容团队 尽管GLP-1药物疗效显著，但它们远非"无需参与"的神奇药物。与青霉素或脊髓灰质炎疫苗等不同，GLP-1的效果依赖于使用者自身的 积极配合，尤其在饮食习惯方面。 点击关注，追踪最新GLP-1资讯 在服用GLP-1类药物（如Ozempic、Wegovy、Mounjaro、Zepbound、Trulicity等）的人看来，这些药物似乎能带来奇迹。美国约70%的 成年人被归类为超重或肥胖， 估计已有超过12%的人尝试过GLP-1类药物，其中不少人减重超过10%。 但药物带来的转变不只是体重 数字的变化，更需要患者主动配合饮食和生活方式。 最初在2005年获批用于2型糖尿病治疗的GLP-1药物，不仅能调节血糖，还能改善脂肪肝、减轻体重相关的健康问题（如膝盖疼痛、胃食 管反流、睡眠呼吸暂停等）。此外，它们也能改善血脂、降低血压，并减少心脑血管疾病的发生风险，已获得美国食品药品管理局批准 用于患有相关心血管疾病的肥胖患者。 新兴研究还发现，这些药物可能帮助抑制酒精、烟草以及其他成瘾行为，甚至减轻冲动性消费的 倾向。 ▍为什么饮食管理如此关键？ 有两个主要原因。首先，合理饮食可以减轻常见 ...

Core Viewpoint - The article emphasizes the importance of a balanced approach to weight loss, highlighting that simply losing weight without maintaining muscle can lead to a lack of vitality and poor body composition [1]. Group 1: Weight Loss Strategies - Avoiding dieting for weight loss is crucial, as it can lead to rapid weight loss but may not improve body shape due to muscle protein breakdown and increased fat ratio [2]. - A balanced diet with sufficient nutrients is essential, focusing on whole grains and fresh fruits and vegetables while avoiding high-energy foods with added sugars [2]. Group 2: Exercise Recommendations - Engaging in moderate-intensity aerobic exercise for at least 150 minutes per week, combined with strength training, is recommended for effective weight loss [3]. - Women should assess their joint flexibility, muscle strength, and cardiovascular fitness before starting strength training, gradually increasing difficulty [3]. Group 3: Nutritional Guidance - Adequate intake of high-quality protein is vital for muscle growth and enhancing fat burning efficiency during exercise [4]. - Insufficient protein intake can lead to a negative nitrogen balance, resulting in a lower basal metabolic rate and making weight loss more difficult [4]. Group 4: Lifestyle Considerations - Maintaining a healthy lifestyle, including regular sleep patterns, avoiding late nights, quitting smoking, and limiting alcohol consumption, is important during the weight loss process [5].